Skip to content

Comparison of unani and allopathic medication for treatment of oral submucous fibrosis

Comparison of Unani formulations Zuroor-e-Qula and Jawarish Amla sada with allopathic antioxidants in management of patients with early-intermediate stage oral submucous fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019734
Enrollment
120
Registered
2019-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Zuroor-e-Qula and Jawarish Amla sada: Jwarish amla sada to be taken with the dose of 6 grams, twice daily for 12 weeks. Drug Zuroor-e-Qula will be given with the instructions to apply o

Sponsors

Ministry of AYUSH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Patients with current or previous use of any form of smokeless tobacco and/or areca nut (any duration and frequency) ii. Patients having early-intermediate stage OSMF designated as Grade I and II by the grading system proposed by Kerr et al (29). iii. Patients willing to quit the habit of smokeless tobacco and/or areca nut. iv. Patients willing to accept regular follow-up protocol

Exclusion criteria

Exclusion criteria: i. Patients having advanced stage OSMF designated as Grade III, IV or V by the grading system proposed by Kerr et al. ii. Any significant medical condition such as scleroderma, anemic stomatitis and diabetes that would interfere with the safety, treatment or compliance with the protocol. Known diabetics or those with altered blood sugar values at the baseline assessment will be excluded from the study. iii. Patients with known allergy or contra-indication to any of the ingredients of the test drugs. iv. Patients already undergoing treatment for OSMF. v. Pregnant and lactating females. vi. Patients having concomitant pericoronitis or any other dental condition leading to trismus.

Design outcomes

Primary

MeasureTime frame
a) Inter-incisal mouth opening b) Tongue protrusion c) Range of jaw movements d) Burning sensation/painTimepoint: every 2 weeks for 3 months:

Secondary

MeasureTime frame
a) Adverse events or side effects reported after taking the Unani formulations. b) The impact of OSMF on quality of life of the patients will be assessed. c) Changes in the oxidative stress. d) Change in the nutritional status. e) Habit cessation success rate at 12-week follow-up.Timepoint: every 2 weeks for 3 months

Countries

India

Contacts

Public ContactArpita Rai

Faculty of Dentistry, Jamia Millia Islamia

arai@jmi.ac.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026